MarkDStegallMD

General Surgery • Rochester, MN

Transplantation

Professor, Surgery, Mayo Medical School

Join to view full profile

Dr. Stegall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stegall's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Summary

I am a Transplant surgeon and researcher who has been at Mayo Clinic Rochester since 1998. I have performed more than 2000 kidney transplants.

My major clinical and research interests involve new therapies that improve the outcomes of transplant recipients. Specifically I am interested in overcoming antibody barriers to transplantation, management of obesity and diabetes in Transplant recipients and developing novel immunosuppressive including total withdrawal/tolerance protocols. My group is also interested in computer assisted assessment of Transplant biopsies.

I also am the Director of the Multicenter Transplant Alliance (mtaconsortium.com), a clinical research group aimed at facilitating novel, high-impact clinical trials in transplantation.

Mark D. Stegall, M.D.

My Bibliography

Mark D. Stegall, MD (0000-0002-1392-0792)

ORCID record for Mark D. Stegall, MD. ORCID provides an identifier for individuals to use with their name as they engage in research, scholarship, and innovatio

Education & Training

University of Wisconsin Hospitals and ClinicsResidency, Surgery, 1991 - 1993
New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1984 - 1991
Columbia University Vagelos College of Physicians and SurgeonsClass of 1984
Harvard UniversityAB, Biology , Magna cum laude, 1974 - 1979

Certifications & Licensure

MN State Medical License 1998 - 2025
CO State Medical License 1993 - 1999
WI State Medical License 1991 - 1993
NY State Medical License 1986 - 1992
American Board of Surgery Surgery

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors Start of enrollment: 2005 Mar 01
Terminated
Phase 4
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients. Start of enrollment: 2005 Dec 01
Completed
Phase 4
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients Start of enrollment: 2001 Apr 01
Completed
Phase 4
A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients. Start of enrollment: 2005 Mar 01
Completed
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant Start of enrollment: 2008 Mar 01
Completed
Phase 1, Phase 2
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates Start of enrollment: 2008 Jun 01
Completed
Phase 2
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant Start of enrollment: 2010 Mar 01
Terminated
Phase 1, Phase 2
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients Start of enrollment: 2010 Oct 05
Recruiting
Not Applicable
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation Start of enrollment: 2011 Dec 01
Terminated
Phase 2
Validation of Gene Expression Markers of Renal Allograft Functional Decline Start of enrollment: 2013 Mar 01
Completed
The TOGETHER Project - Heart Start of enrollment: 2017 Dec 07
Completed
The TOGETHER Project - Kidney RNA-seq Validation Start of enrollment: 2016 Nov 17
Completed
Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation Start of enrollment: 2019 May 09
Completed
Phase 2
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx Start of enrollment: 2021 Oct 14
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Physician-Directed Mycophenolate Mofetil Dose Reduction After Kidney Transplantation: A Multicenter Real Word Experience.
Hani M Wadei, Namrata Parikh, Sarah Suliman, Ahmed Abdelrheem, Walter D Park
Transplantation Proceedings. 2024-12-01
1 citations
Renal Disease and Kidney Transplantation in Hispanic American Persons.
Girish K Mour, Aleksandra Kukla, Andres Jaramillo, Daniel S Ramon, Hani M Wadei
Kidney360. 2024-11-01
2 citations
Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival.
Amanda Klein, Luke Kosinski, Alexandre Loupy, Eric Frey, Mark Stegall
American Journal of Transplantation. 2024-10-01

Journal Articles

Long‐Term Outcomes of Eculizumab‐Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor‐Specific Antibodies
Matthew Everly, Lynn D Cornell, Carrie A Schinstock, Andrew J Bentall, Mark D Stegall, American journal of transplantation

Press Mentions

A Mayo Clinic AI Program Could Soon Be Part of Kidney Transplant CareApril 1st, 2023
Five Ways AI Promises to Transform Organ TransplantsMarch 21st, 2023
Mayo Clinic Study Expands Criteria to Be a Living Kidney DonorJuly 14th, 2021
Join now to see all